Elizabeth Riggs, M.D. Preventive Medicine - Occupational Medicine Medicare: Accepting Medicare Assignments Practice Location: 1321 Unity Pl, Suite B, Lafayette, IN 47905 Phone: 765-446-1362 Fax: 765-446-1007 |
Carl D Griffin, MD Preventive Medicine - Occupational Medicine Medicare: Medicare Enrolled Practice Location: 2600 Greenbush St, Lafayette, IN 47904 Phone: 765-448-8000 Fax: 765-448-8702 |
Dr. John Carroll Shively, M.D. Preventive Medicine - Occupational Medicine Medicare: Not Enrolled in Medicare Practice Location: 3701 State Road 26 E, Lafayette, IN 47905 Phone: 765-448-5800 Fax: 765-448-2032 |
News Archive
US Oncology, Inc., the leading oncology services company uniting the nation's largest cancer treatment and research network to expand patient access to high-quality, cost-effective cancer care and advance the science of cancer care, has been named to FORTUNE magazine's World's Most Admired Companies list for 2010.
"South Korea said on Monday that it would send 6.5 billion won, or $5.7 million, in aid to North Korea through UNICEF, the United Nations children's agency," the New York Times reports.
VistaGen Therapeutics, Inc., a stem cell technology company focused on drug discovery and development, today announced the successful completion of its initial Phase 1 safety study of AV-101, the Company's novel orally available prodrug candidate for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects approximately 1.8 million people in the U.S.
A new study by researchers at Roche in Basel, Switzerland has identified a key brain region of the neural circuit that controls social behavior. Increasing the activity of this region, called the habenula, led to social problems in rodents, whereas decreasing activity of the region prevented social problems.
Genzyme Corp.today said it welcomed the Centers for Medicare and Medicaid Services' decision not to include oral medications without IV equivalents in Medicare's End Stage Renal Disease patient benefit. According to the final rule, these medications, including Genzyme's Renvela (sevelamer carbonate), will not be included in the bundle until January 1, 2014.
› Verified 9 days ago